Lianbio
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 6
- Registration Number
- NCT06206278
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳The Second Hospital Lanzhou University, Lanzhou, Gansu, China
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 4
- Registration Number
- NCT06032936
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Jilin Cancer Hospital, Changchun, Jilin, China
Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 163
- Registration Number
- NCT05629390
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
🇨🇳Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Renmin Hospital of Wuhan University, Wuhan, Hubei, China
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 7
- Registration Number
- NCT05621525
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
- Conditions
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 81
- Registration Number
- NCT05174416
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 45
- Registration Number
- NCT05135871
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- LianBio LLC
- Target Recruit Count
- 80
- Registration Number
- NCT05019794
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China